Esbriet (pirfenidone) is an anti-inflammatory and anti-fibrotic drug which has been found to be effective in slowing down the rate of fibrosis in the lung tissue of patients with pulmonary fibrosis (PF). But which PF patients would benefit most from the drug?
This video from MD Magazine TV identifies the types of patients that are ideal for the use of esbriet. Dr. Benjamin Kramer from Genentech discusses some of the criteria a patient must meet to be considered for esbriet. He shares that patients must be aware of the side effects of esbriet and how they’ll be managed, along with the fact that esbriet will not cure their pulmonary fibrosis but merely slow down the progression of the disease.
Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.